We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Medicaid Rate Improvements Drive Elevance's 2027 Margin Recovery?
Read MoreHide Full Article
Key Takeaways
Elevance expects Medicaid margins to improve in 2027, supported by higher rates and tighter cost management.
Medicaid revenues rose 5.7% to $15 billion in Q3, while reimbursement rates still lag elevated medical costs.
Elevance targets long-term Medicaid margins of 2-4%, but uneven state rate hikes and acuity shifts pose risks.
Elevance Health, Inc. (ELV - Free Report) is positioning for a Medicaid margin recovery in 2027, supported by improving reimbursement rates and tighter cost management. Recent rate actions benefited third-quarter performance, placing Medicaid margins slightly ahead of the company's previous full-year outlook. However, reimbursement rates have yet to fully reflect elevated medical costs.
The financial implications are significant. Medicaid generated approximately $15 billion in third-quarter operating revenues, up 5.7% year over year, underscoring its importance to Elevance's Health Benefits business. The company's consolidated benefit expense ratio stood at 90.6% in the third quarter, although a Medicaid-specific ratio was not separately disclosed. With medical expenses consuming a substantial portion of premiums, even modest margin improvements could meaningfully support profitability. Elevance expects Medicaid margins to improve in 2027 and maintains a long-term margin target of 2-4%, although reaching that range will require sustained progress.
States are increasingly incorporating recent medical cost trends into their 2027 rate calculations, although adjustments vary across markets. Meanwhile, Elevance is strengthening behavioral health oversight, care management and targeted network actions to contain expenses. The effectiveness of these initiatives will be critical, particularly as potential membership and acuity shifts tied to new community engagement requirements introduce additional uncertainty.
Higher reimbursement rates will need to keep pace with medical cost trends for Elevance to achieve meaningful Medicaid margin expansion. While 2027 offers a potential turning point, uneven state rate adjustments, elevated medical costs and changing membership dynamics could constrain the pace of recovery.
How Are ELV's Peers Positioned?
Elevance Health's Medical sector peers, Centene Corporation (CNC - Free Report) and Molina Healthcare, Inc. (MOH - Free Report) , also face Medicaid reimbursement and medical cost pressures.
Centene reported a Medicaid HBR of 93.6% in the third quarter, up 20 basis points year over year but down 30 basis points sequentially. The sequential improvement suggests some easing in medical cost pressure, although CNC's ratio remains above its year-ago level. Rate adjustments will remain important to sustaining margin improvement.
Molina's Medicaid medical care ratio rose 100 basis points year over year to 93%. Although MOH's Medicaid premium revenues increased 2.3% to $8.2 billion, its medical margin declined to $577 million from $639 million. This reflects the difficulty of converting premium growth into stronger profitability amid elevated medical costs.
ELV’s Price Performance, Valuation & Estimates
Shares of Elevance Health have risen 22.6% year to date compared with the industry’s 9.4% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, ELV trades at a forward price-to-earnings ratio of 14.45 compared with the industry average of 16.25. ELV carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Elevance Health’s 2026 earnings is pegged at $28.70 per share, followed by a 4.1% year-over-year improvement in 2027.
Image: Bigstock
Can Medicaid Rate Improvements Drive Elevance's 2027 Margin Recovery?
Key Takeaways
Elevance Health, Inc. (ELV - Free Report) is positioning for a Medicaid margin recovery in 2027, supported by improving reimbursement rates and tighter cost management. Recent rate actions benefited third-quarter performance, placing Medicaid margins slightly ahead of the company's previous full-year outlook. However, reimbursement rates have yet to fully reflect elevated medical costs.
The financial implications are significant. Medicaid generated approximately $15 billion in third-quarter operating revenues, up 5.7% year over year, underscoring its importance to Elevance's Health Benefits business. The company's consolidated benefit expense ratio stood at 90.6% in the third quarter, although a Medicaid-specific ratio was not separately disclosed. With medical expenses consuming a substantial portion of premiums, even modest margin improvements could meaningfully support profitability. Elevance expects Medicaid margins to improve in 2027 and maintains a long-term margin target of 2-4%, although reaching that range will require sustained progress.
States are increasingly incorporating recent medical cost trends into their 2027 rate calculations, although adjustments vary across markets. Meanwhile, Elevance is strengthening behavioral health oversight, care management and targeted network actions to contain expenses. The effectiveness of these initiatives will be critical, particularly as potential membership and acuity shifts tied to new community engagement requirements introduce additional uncertainty.
Higher reimbursement rates will need to keep pace with medical cost trends for Elevance to achieve meaningful Medicaid margin expansion. While 2027 offers a potential turning point, uneven state rate adjustments, elevated medical costs and changing membership dynamics could constrain the pace of recovery.
How Are ELV's Peers Positioned?
Elevance Health's Medical sector peers, Centene Corporation (CNC - Free Report) and Molina Healthcare, Inc. (MOH - Free Report) , also face Medicaid reimbursement and medical cost pressures.
Centene reported a Medicaid HBR of 93.6% in the third quarter, up 20 basis points year over year but down 30 basis points sequentially. The sequential improvement suggests some easing in medical cost pressure, although CNC's ratio remains above its year-ago level. Rate adjustments will remain important to sustaining margin improvement.
Molina's Medicaid medical care ratio rose 100 basis points year over year to 93%. Although MOH's Medicaid premium revenues increased 2.3% to $8.2 billion, its medical margin declined to $577 million from $639 million. This reflects the difficulty of converting premium growth into stronger profitability amid elevated medical costs.
ELV’s Price Performance, Valuation & Estimates
Shares of Elevance Health have risen 22.6% year to date compared with the industry’s 9.4% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, ELV trades at a forward price-to-earnings ratio of 14.45 compared with the industry average of 16.25. ELV carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Elevance Health’s 2026 earnings is pegged at $28.70 per share, followed by a 4.1% year-over-year improvement in 2027.
Image Source: Zacks Investment Research
ELV currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.